Pfizer stock: India profit rises on one-time Minipress gain
Published on 11/13/2026 at 02:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPfizer India profit and revenue
- Pfizer Limited increased second-quarter revenue while underlying profit before exceptional items also advanced.
- A payment linked to the discontinuation of Minipress XL materially lifted reported earnings.
- First-half operating cash generation declined from the year-earlier period.
Pfizer Limited reported stronger operating performance in its second quarter of fiscal 2027, although a one-time gain linked to Minipress XL materially increased reported profit. The results were reported on Tuesday, November 3, 2026, and covered the quarter ended September 2026.
According to Kotak Neo, revenue from operations rose 13.2 percent year over year to 726.86 crore Indian rupees. Profit before exceptional items and tax increased 13.9 percent to 290.77 crore Indian rupees, indicating that the underlying business grew ahead of the reported headline.
One-time gain lifts reported profit
Net profit climbed 65.7 percent to 313.25 crore Indian rupees. The result included an exceptional gain of 132.06 crore Indian rupees, net of related expenses, after Pfizer Inc. decided to discontinue manufacturing Minipress XL from September 7, 2026. Pfizer Limited is due to receive a lump-sum payment linked to the discontinuation of the product's marketing, distribution and sale in India.
The distinction between reported and underlying earnings is important for investors. Earnings per share before exceptional items rose to 47.09 Indian rupees from 41.32 Indian rupees a year earlier, while total expenses increased to 483.42 crore Indian rupees from 428.82 crore Indian rupees.
First-half cash flow remains a focus
For the six months ended September 2026, revenue from operations increased 10.8 percent to 1,380.03 crore Indian rupees. Profit before exceptional items and tax grew 10.2 percent to 567.45 crore Indian rupees, while reported net profit advanced 36 percent to 517.72 crore Indian rupees.
Operating cash generation was 358.99 crore Indian rupees in the first half, compared with 599.47 crore Indian rupees in the year-earlier period. Kotak Neo attributed the decline partly to movements in income-tax payments, leaving cash conversion as an additional point for investors to monitor alongside the company's revenue growth.
Pfizer Limited in India
Pfizer Limited markets more than 150 products across 15 therapeutic areas and four business categories in India. Its activities include pharmaceutical products and manufacturing operations serving the Indian market. The company is part of the wider Pfizer group, whose product decisions can affect Pfizer Limited's local portfolio and earnings.
Pfizer Limited results snapshot
- Company: Pfizer Limited
- Reporting period: Second quarter of fiscal 2027, ended September 2026
- Revenue from operations: 726.86 crore Indian rupees
- Net profit: 313.25 crore Indian rupees
- Exceptional gain: 132.06 crore Indian rupees
- First-half operating cash flow: 358.99 crore Indian rupees
